Login / Register The Most Trusted Name in Medical Education

Oncology

From breast cancer to myeloma and gastric cancer, Elsevier's Office of Continuing Medical Education offers complimentary CME courses for a variety of oncology subject matters.

910703 116 x 140

Current and Future Therapies for Cytomegalovirus (CMV) Infection

Format: Webcast

Cytomegalovirus (CMV) infection remains a frequent complication in hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT) recipients. In addition to causing a variety of end-organ diseases, CMV infection is also associated with rejection after SOT and with graft versus host disease (GVHD) after HSCT, as well as with increased risk of secondary bacterial and fungal infections. Antiviral prophylaxis, more commonly used after SOT, is effective against direct and indirect effects of CMV infection, but may lead to overtreatment. Preemptive therapy, more commonly used after HSCT, is based on surveillance, and targets therapy to patients at highest risk. Several antiviral agents are currently available for CMV management; however, their use may be associated with myelosuppression and nephrotoxicity. Novel antiviral therapies with different mechanisms of action are in late-stage development and hold the promise of reducing CMV-related morbidity and mortality.

Take Course »

Credits: 1.0 AMA PRA Category 1 Credit(s)™
MEDX ONC 125x125pxFB

Evidence-based Medicine in Oncology Practice: Challenges in Today’s Healthcare Environment

Format: Live Meeting

Medical Education Exchange (MEDX) will host a MEDX Regional Oncology CME/CNE/CE Conference in Fall 2017 for the community-based oncology care team. Both clinical and topical content for the conference will focus on the fundamental principles of oncology care and will be created with the Oncology Care Model (OCM) and The Medicare Access and CHIP Reauthorization Act of 2015 Quality Payment Program (MACRA QPP) in mind. In addition to the live regional conference, MEDX will partner with Rockpointe Oncology on the development of the clinical content.

Register Now»

Credits: CME/CPE/CNE
138 17 287 JS 140x117

Immunotherapy: The Wave of the Future in Bladder Cancer?

Format: Supplement

This article reviews the role of immunotherapy in the treatment of locally advanced and metastatic urothelial cell carcinoma (UC). It describes the basic principles of cancer immunotherapy, as they relate to management of UC, and summarizes clinical data on current and investigational therapeutic approaches. Two immune checkpoint inhibitors are now approved for treatment of advanced UC in the United States, and the article discusses their unique response patterns and side effect profiles to help oncology clinicians appropriately incorporate these agents into patient care.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910659 116 x 140

ESMO 2016: A Therapeutic Update on the Management of Patients with Breast Cancer

Format: Medical Meeting Reporter

Results from several key clinical trials evaluating new therapeutic approaches for patients with metastatic breast cancer (MBC) were presented at the European Society for Medical Oncology (ESMO) 2016 Congress on October 7–11, 2016 in Copenhagen, Denmark. These results have the potential to change clinical practice. In this activity, you will listen to two leading experts in breast cancer management and research as they review the key data presented at ESMO 2016 and discuss the implications for current practice and future research.

Register »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910668 116 x 140

ESMO 2016: A Therapeutic Update on Metastatic Castration Resistant Prostate Cancer

Format: Medical Meeting Reporter

Results from several key clinical trials evaluating new therapeutic approaches for patients with metastatic castration resistant prostate cancer were presented at the European Society for Medical Oncology (ESMO) 2016 Congress on October 7–11, 2016 in Copenhagen, Denmark. These results indicate that metastatic castration resistant prostate cancer is not a single disease and that biomarkers may play an essential role in deciding on best therapy for your patients. In this activity, you will listen to two leading experts in metastatic castration resistant prostate cancer management and research as they review the key data presented at ESMO 2016 and discuss the implications for current practice and future research.

Register »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910673 116 x 140

ESMO 2016: A Therapeutic Update on the Management of Patients with Non-Small Cell Lung Cancer

Format: Medical Meeting Reporter

Potentially practice-changing data from clinical trials in non-small cell lung cancer (NSCLC) were presented at the European Society for Medical Oncology (ESMO) 2016 Congress on October 7–11 in Copenhagen, Denmark. These data may not only lead to new treatment options but also help clinicians use existing treatment options more effectively. In this video presentation, two leading experts in the management of NSCLC review key results presented at ESMO 2016 and provide insights on how the results may influence practice today. 

Register »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
SNO 116x141

New Considerations for the Treatment of Glioblastoma Multiforme: Evaluating the Potential for Immune Checkpoint Inhibitors

Format: Webcast

The content for this activity is based on the satellite symposium, “New Considerations for the Treatment of Glioblastoma Multiforme: Evaluating the Potential for Immune Checkpoint Inhibitors”, that was presented at the 21st Annual Meeting of the Society for Neuro-Oncology in Scottsdale, Arizona on November 17, 2016. Glioblastoma multiforme (GBM) remains one of the most feared of all malignancies due to its aggressive nature and correspondingly low survival rates. Recently, immunotherapies – particularly immune checkpoint inhibitors – have shown promise in treating patients with GBM in cases where conventional treatment options have failed. This archived symposium activity will provide participants with the opportunity to optimize the diagnosis and management of patients with GBM, including new data and remaining challenges resulting from recent clinical trials in the use of immune checkpoint inhibitors.

Take Course »

Credits: 1.50 AMA PRA Category 1 Credit(s)™
910692 116 x 140

ASCO GU 2017: A Therapeutic Update on the Management of Patients with Prostate Cancer

Format: Conference Reporter

Ground-breaking research on the molecular and genetic properties of prostate cancer (PC) was presented at the 2017 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO), held on February 16–18 in Orlando, Florida. This research provided many insights on the genetic changes associated with disease progression and the development of treatment resistance that may help inform treatment decisions for patients with PC in the near future. In this video presentation, three leading experts in the management of PC review key results presented at ASCO-GU 2017 and provide their thoughts on how the results may influence current research and practice.

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™
OA 125 x 125

ESMO 2016 Conference: Perspectives & Analysis: Breast Cancer, Lung Cancer and Non-Small Cell Lung Cancer

Format: Medical Meeting Reporter

Results from several key clinical trials evaluating therapeutic approaches for patients with metastatic breast cancer, metastatic castration resistant prostate cancer and non-small cell lung cancer were presented at the European Society for Medical Oncology (ESMO) 2016 Congress on October 7–11, 2016 in Copenhagen, Denmark. Participate in any of the following activities and hear leading experts in their respective fields discuss the implications for current practice and future research.

Take Courses »